Atossa Therapeutics, Inc. (FRA:YAG2)

Market Cap	61.43M -42.2%
Revenue (ttm)	n/a
Net Income	-25.72M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6,065
Open	0.5570
Previous Close	0.5530
Day's Range	0.5570 - 0.5570
52-Week Range	0.4850 - 1.0820
Beta	n/a
RSI	38.11
Earnings Date	Mar 27, 2026

About Atossa Therapeutics

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Thera...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 15
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YAG2

Financial Performance

Financial numbers in USD